prostacyclin product myocardi infarct acut phase follow-up twenty-f patient myocardi infarct acut phase follow-up regard vivo product prostacyclin thromboxan measur major urinari metabolit alpha patient product exercis test week discharg patient vivo product prostacyclin acut phase infarct process inabl decreas releas heart muscl enzym women exercis toler test none patient increas prostacyclin product contrast healthi volunt signific increas differ patient increas prostacyclin product acut phase follow-up year myocardi infarct cardiac event patient expect increas prostacyclin product associ infarct reason patient group primari infarct 